Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: A RE-LY substudy

Heart

Volumn 100, Issue 15, 2014, Pages 1193-1200

  Hijazi, Ziad ^a   Oldgren, Jonas ^a   Andersson, Ulrika ^a   Connolly, Stuart J ^b   Ezekowitz, Michael D ^c   Hohnloser, Stefan H ^d   Reilly, Paul A ^e   Siegbahn, Agneta ^a   Yusuf, Salim ^b   Wallentin, Lars ^a  

^a UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; DABIGATRAN; TROPONIN I; WARFARIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; STROKE; SURVIVAL RATE; SWEDEN; TROPONIN T;

EID: 84904040468     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304872     Document Type: Article

References (28)

1. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-52. (Pubitemid 28446646)
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
3. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
4. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long- Term Anticoagulation Therapy (RE-LY) Substudy. Circulation 2012;125:1605-16.
5. Hijazi Z, Siegbahn A, Andersson U, et al. High Sensitivity Troponin I for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. Circulation 2013; doi:10.1161/CIRCULATIONAHA.113.006286 [ published Online First: Epub Date].
6. Hijazi Z, Wallentin L, Siegbahn A, et al. High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin. J Am Coll Cardiol 2013; doi:10.1016/j.jacc.2013.07.093 [ published Online First: Epub Date].
7. Hijazi Z, Wallentin L, Siegbahn A, et al. N- Terminal pro-B- Type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013;61:2274-84.
8. Roldan V, Marin F, Diaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. JTH 2012;10:1500-7.
9. de Filippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.
10. Eggers KM, Lagerqvist B, Venge P, et al. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long- Term mortality. Circulation 2007;116:1907-14. (Pubitemid 350287086)
11. Gackowski A, Isnard R, Golmard JL, et al. Comparison of echocardiography and plasma B- Type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004;25:1788-96. (Pubitemid 39330229)
12. Lindahl B, Lindback J, Jernberg T, et al. Serial analyses of N- Terminal pro-B- Type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: A Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005;45:533-41. (Pubitemid 40222247)
13. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B- Type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-71. (Pubitemid 41785867)
14. Xue Y, Clopton P, Peacock WF, et al. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 2011;13:37-42.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
16. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long- Term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-10, 10 e1-e2.
17. Johnston N, Jernberg T, Lindahl B, et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004;37:210-16. (Pubitemid 38221569)
18. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. (Pubitemid 26072233)
19. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
20. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino- Terminal pro-B- Type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881-9.
21. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-9. (Pubitemid 46589928)
22. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68. (Pubitemid 50011582)
23. Eggers KM, Lind L, Ahlstrom H, et al. Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J 2008;29:2252-8.
24. Goetze JP, Friis-Hansen L, Rehfeld JF, et al. Atrial secretion of B- Type natriuretic peptide. Eur Heart J 2006;27:1648-50. (Pubitemid 44025348)
25. Hijazi Z, Oldgren J, Siegbahn A, et al. Biomarkers in atrial fibrillation: A clinical review. Eur Heart J 2013;34:1475-80.
26. Jeremias A, Gibson CM. Narrative review: Alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005;142:786-91. (Pubitemid 40593781)
27. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-91. (Pubitemid 33139098)
28. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4. (Pubitemid 27344221)